Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | CTSC | P53634 | 1/20 | 0.51 |
| ▸ | IDH2 | P48735 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | CD38 | P28907 | 1/20 | 0.47 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12501156 | 0.80 | CYP1A2 (0.65) | EGFRABCG2TSHRHTTLMNA | |
| SCHEMBL4140858 | 0.78 | CTSC (0.67) | CTSCIDH2KDR | |
| SCHEMBL4131488 | 0.77 | KDM4E (0.59) | EGFRABCG2CTSCIDH2LMNA | |
| SCHEMBL4131075 | 0.77 | CTSC (0.56) | EGFRABCG2CTSCIDH2LMNA | |
| SCHEMBL12501138 | 0.77 | MAPK1 (0.59) | EGFRABCG2TSHRHTTLMNA | |
| SCHEMBL30398394 | 0.77 | ABCG2 (0.64) | EGFRABCG2TSHRHTTCTSC | |
| SCHEMBL806052 | 0.77 | ABCG2 (0.64) | EGFRABCG2TSHRHTTCTSC | |
| SCHEMBL13653032 | 0.76 | LMNA (0.66) | EGFRABCG2TSHRHTTCTSC | |
| SCHEMBL15184200 | 0.75 | EGFR (0.57) | EGFRABCG2TSHRHTTLMNA | |
| SCHEMBL30754777 | 0.75 | LMNA (0.65) | EGFRABCG2TSHRHTTCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | EGFR 712/4885ABCG2 2473/4885TSHR 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.